Busulfan
From Wikipedia, the free encyclopedia
Busulfan
|
|
Systematic (IUPAC) name | |
1,4-bis(methylsulfonyloxy)butane | |
Identifiers | |
CAS number | |
ATC code | L01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C6H14O6S2 |
Mol. mass | 246.304 g/mol |
Pharmacokinetic data | |
Bioavailability | 80% (oral) |
Protein binding | 32.4% |
Metabolism | Hepatic |
Half life | 2.5 hours |
Excretion | ? |
Therapeutic considerations | |
Licence data |
|
Pregnancy cat. |
? |
Legal status |
℞ Prescription only |
Routes | Oral, parenteral |
Busulfan is a chemotherapy drug that is an alkylating agent (slows the growth of cancer cells). It is marketed in the U.S. by GlaxoSmithKline under the brand name Myleran, and has been in clinical use since 1959. Its chemical designation is 1,4-Butanediol dimethanesulfonate.
Contents |
[edit] Uses
Currently, its main uses are in bone marrow transplantation, especially in chronic myelogenous leukemia (CML), where it is used as a conditioning drug.
The drug was recently used in a study to examine the role of platelet-transported serotonin in liver regeneration.[1]
Busulfan is now available in an IV formulation marketed as Busulfex by PDL BioPharma, Inc.
[edit] Toxicity and side effects
Toxicity may include pulmonary fibrosis and hyperpigmentation. 1,4-Butanediol dimethanesulfonate is listed by the IARC as a Group 1 carcinogen.
Busulfan also induces thrombocytopenia, a condition of lowered blood platelet count and activity.
[edit] References
- ^ Lesurtel M, Graf R, Aleil B, Walther D, Tian Y, Jochum W, Gachet C, Bader M, Clavien P (2006). "Platelet-derived serotonin mediates liver regeneration". Science 312 (5770): 104–7. PMID 16601191.